Neuphoria Therapeutics Inc. Common Stock

GoPro has retained financial advisers to explore a potential sale following unsolicited inquiries. Brookfield Asset Management acquired World Freight Company for $1.2 billion. Multiple companies announced strategic reviews including Neuphoria Therapeutics and XBP Global Holdings. YesCare Corp. and Spanish Broadcasting System filed for Chapter 11 ...

Neuphoria Therapeutics reported achieving last patient last visit milestone in AFFIRM-1 Phase 3 trial for BNC-210 in social anxiety disorder, with topline data expected in early Q4 2025. The company extended its cash runway through fiscal Q2 2027 and reported a reduced net loss compared to the previous year.

Neuphoria Therapeutics has completed target enrollment of 332 participants in its Phase 3 AFFIRM-1 trial for BNC-210, a potential treatment for social anxiety disorder, with initial Phase 3 data expected in early Q4 2025.